Core Viewpoint - The company Hansai Aitai-B (03378) has seen a rebound of nearly 6%, with a current increase of 5.12%, trading at HKD 18.08, with a transaction volume of HKD 10.4874 million [1] Group 1: Clinical Development - The company announced that its innovative drug, HX111, has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials within China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignant tumors compared to normal tissues during preclinical studies, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Future Plans - The company aims to continue its efforts in clinical development to bring more novel first-in-class (FIC) drugs to market [1]

Core Viewpoint - The company Hansai Aitai-B (03378) has seen a rebound of nearly 6%, with a current increase of 5.12%, trading at HKD 18.08, and a transaction volume of HKD 10.4874 million [1] Group 1: Clinical Development - The company announced that its innovative drug, HX111, has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials within China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignant tumors compared to normal tissues during preclinical studies, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Future Plans - The company aims to continue its efforts in clinical development to bring more novel first-in-class drugs to market [1]

Core Viewpoint - The company Hansa Biopharma-B (03378) has seen a nearly 6% rebound in its stock price following the approval of its innovative drug HX111 for clinical trials in China by the National Medical Products Administration [1] Group 1: Company Developments - Hansa Biopharma announced that its innovative drug injection HX111 has been approved for clinical trials in China [1] - HX111 is a first-in-class OX40-targeted antibody-drug conjugate (ADC), which has shown overexpression in several malignancies compared to normal tissues, making it a suitable target for ADC [1] - HX111 is the third first-in-class molecule to advance to clinical development, following HX009 and HX044, both of which are bispecific antibody therapies [1] Group 2: Market Reaction - Following the announcement, Hansa Biopharma's stock price increased by 5.12%, reaching HKD 18.08, with a trading volume of HKD 10.4874 million [1]

Group 1 - The port and shipping stocks in Hong Kong and A-shares experienced a significant increase, with China COSCO Shipping Holdings (1919.HK) rising over 7% and Pacific Shipping increasing over 4% [1][2] - In A-shares, Beibu Gulf Port rose over 6%, Xiamen Port increased over 5%, and companies like Qinhuangdao Port and Rizhao Port also saw gains [1][2] Group 2 - Xiamen Port is set to merge with the provincial port group, with the actual controller changing to the Fujian Provincial State-owned Assets Supervision and Administration Commission [2] - Pacific Shipping received an increase in shareholding from M&G Plc, which raised its stake from 4.97% to 5.05% after acquiring 3.557 million shares on August 7 [2] - The Baltic Dry Index rose by 1.1% last Friday (14th), marking its 13th consecutive day of increase, reaching 1595 points, the highest since July 20, driven by increased demand for various types of vessels [2] - The Capesize vessel rate index increased by 0.8% to 2402 points, while the Panamax vessel rate index rose by 1.5% to 1824 points, reaching the highest level since October 18 of the previous year [2]

据悉，要约人为厦门港务控股全资拥有，厦门港务控股为福建港口集团全资拥有(而福建港口集团则为 福建省国资委控制)。 此外，公司已向联交所申请批准H股于2022年6月6日上午九时正起恢复买卖。 厦门港务(03378.HK)公告，于2022年6月2日，要约人厦门港务投资运营有限公司及公司已订立合并协 议，据此要约人及公司已同意根据合并协议的条款及条件(包括前提条件及该等条件)实施合并。于合并 后，公司将根据中国公司法及其他适用中国法律被要约人吸收合并。 合并的理由及裨益包括：(1)当前公司作为上市平台的境外融资功能受限；(2)合并将有利于业务长远发 展；(3)H股退市为H股股东提供以溢价出售流动性欠佳H股的绝佳退出机会。 根据合并协议，待前提条件及该等条件达成后，要约人将以现金支付以下金额的注销价：(a)向H股股东 支付每股H股2.25港元，注销价较5月26日收市价每股H股约1.45港元溢价约55.17%；及(b)向内资股股东 支付每股内资股人民币1.923795元。 于前提条件及所有生效条件达成后，公司将根据上市规则第6.15条向联交所申请自愿撤销H股于联交所 的上市地位。 ...

Group 1 - Hansi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. successfully listed on the Hong Kong Stock Exchange on December 23, becoming the 71st listed company in the Optics Valley region [1] - The IPO involved a global offering of 18.321 million shares at an issue price of HKD 32 per share, raising a total of HKD 586 million, with a market capitalization of nearly HKD 4.4 billion [1] - Hansi Aitai focuses on developing innovative drugs for precise treatment of cancer and autoimmune diseases, with a pipeline of 10 candidate drugs, including 3 in clinical stages and 7 in preclinical stages [1] Group 2 - The founder of Hansi Aitai, Zhang Faming, is a professor and doctoral supervisor at Wuhan University School of Pharmacy, and has been an entrepreneur in the innovative drug field for 16 years [2] - The total number of listed companies in the Optics Valley region has reached 71, accounting for over 60% of the city's total and approximately one-third of the province's total [2] - In the life and health sector, there are currently 9 listed companies in the Optics Valley, with 6 companies undergoing listing review and 19 companies starting IPO counseling [2]

Group 1: New Listings on Hong Kong Stock Exchange - Nobikang (HK02635) and Qingsong Health (HK02661) had a strong debut, with Nobikang closing at HKD 371 per share, up 363.75%, achieving a total market capitalization of HKD 14.049 billion; Qingsong Health closed at HKD 58.7 per share, up 158.82%, with a total market capitalization of HKD 12.114 billion [1] - Hansai Aitai-B (HK03378) experienced a decline, closing at HKD 17.2 per share, down 46.25%, with a total market capitalization of HKD 2.343 billion [1] - The contrasting performances of these three new stocks reflect investor preferences and the misalignment of fundamentals and valuations, indicating a more rational investment approach [1] Group 2: Upcoming IPOs - Haizhi Technology has submitted a listing application to the Hong Kong Stock Exchange, ranking fifth among industrial-grade AI providers in China by projected 2024 revenue, and first among image-centric AI providers [2] - Longxun Co., Ltd. has also filed for a listing, focusing on high-speed mixed-signal chip design for smart visual terminals and AI applications, leading the domestic video bridging chip market and ranking among the top five globally in the fabless design sector [3] - Weichai Lovol has submitted its listing application, recognized as a leading provider of smart agricultural solutions in China, aiming to enhance agricultural sustainability through intelligent machinery and technology [4] Group 3: Market Performance - On December 23, the Hong Kong stock market index closed at 25,774.14, down 0.11%, with the old biotechnology sector index at 5,488.89, down 0.69%, and the technology sector index at 8,913.83, down 0.29% [5]

Group 1 - Han's Biopharma (3378.HK) listed on the Hong Kong Stock Exchange on December 23, raising a total of HKD 586 million by offering 18.32 million shares at HKD 32 per share, with a market capitalization of nearly HKD 4.4 billion [1] - Following the IPO, the stock price fell significantly, closing at HKD 17.2 per share, representing a decline of 46.25% and a total market value of HKD 2.343 billion [1] - The company, founded in 2014, focuses on developing innovative drugs for precise treatment of cancer and autoimmune diseases, with a pipeline of 10 candidate drugs, including 3 in clinical stages and 7 in preclinical stages [1] Group 2 - The core product, HX009, is a self-developed dual-function antibody fusion protein that has completed Phase I clinical trials in Australia and China, and is currently undergoing Phase Ib/I/IIa clinical trials for advanced melanoma, relapsed/refractory EBV-positive non-Hodgkin lymphoma, and advanced biliary cancer in China [1] - The company also has two other main clinical-stage products: HX301, a multi-target kinase inhibitor in Phase II trials for glioblastoma, and HX044, a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein in Phase I/IIa trials for advanced solid tumors [2] - The founder, Zhang Faming, is a professor and doctoral supervisor at Wuhan University, with a history of entrepreneurship in the innovative drug sector, having established multiple companies in the Wuhan East Lake High-tech Zone, which has a significant number of listed companies in the life and health sector [2]

Core Viewpoint - The company announced that its innovative drug HX111 has been approved by the National Medical Products Administration of the People's Republic of China to conduct clinical trials within the country [1] Group 1: Product Development - HX111 is a first-in-class (FIC) OX40-targeted antibody-drug conjugate (ADC) [1] - Preclinical studies indicate that OX40 is overexpressed in several malignancies, including certain lymphomas, compared to normal tissues, making it a suitable target for ADCs like HX111 [1] - OX40 is also overexpressed in regulatory T cells (Treg) within the tumor microenvironment (TME), which are known to suppress anti-tumor immunity [1] Group 2: Mechanism of Action - The elimination of Treg represents a new mechanism of action (MOA) for cancer immunotherapy, which can be achieved through HX111, indicating potential broad cancer application prospects [1] Group 3: Future Development - HX111 is the third first-in-class molecule to advance to clinical development following HX009 and HX044, both of which are bispecific antibody (BsAb) therapies [1] - The company aims to continue its efforts in clinical development to bring more novel FIC drugs to market [1]

Core Viewpoint - Hansa Biopharma-B (03378.HK) has received approval from the National Medical Products Administration of the People's Republic of China to conduct clinical trials for its innovative drug, HX111, which is a first-in-class (FIC) OX40-targeted antibody-drug conjugate (ADC) [1] Group 1: Product Development - HX111 is identified as a first-in-class OX40-targeted ADC, which shows overexpression in several malignancies, including certain lymphomas, compared to normal tissues, making it a suitable target for ADC therapies [1] - Preclinical studies indicate that OX40 is a tumor-associated antigen (TAA) and is overexpressed in regulatory T cells (Treg) within the tumor microenvironment (TME), which are known to suppress anti-tumor immunity [1] - The mechanism of action (MOA) for HX111 involves the elimination of Tregs, representing a novel approach in cancer immunotherapy with potential applications across various cancers [1] Group 2: Company Strategy - HX111 is the third first-in-class molecule to advance to clinical development following the company's previous dual-specific antibody (BsAb) therapies, HX009 and HX044 [1] - The company aims to continue its efforts in clinical development to bring more innovative FIC drugs to market [1]